欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2022, Vol. 27 ›› Issue (12): 1347-1353.doi: 10.12092/j.issn.1009-2501.2022.12.004

• 麻醉药与脑功能障碍专刊 • 上一篇    下一篇

氯胺酮拟精神症状及奖励机制的研究进展

杨航1,陆方舟2,杨春1,朱伟1   

  1. 1南京医科大学第一临床医学院,南京 211166;2南京医科大学第一附属医院麻醉与围术期医学科,南京 210029,江苏

  • 收稿日期:2022-09-01 修回日期:2022-12-21 出版日期:2022-12-26 发布日期:2023-01-13
  • 通讯作者: 朱伟,男,主任医师,硕士生导师,研究方向:麻醉与重症。 E-mail: zhuweijsph@163.com 杨春,男,副主任医师,教授,博士生导师,研究方向:麻醉与脑科。 E-mail: chunyang@njmu.edu.cn
  • 作者简介:杨航,男,硕士研究生,住院医师,研究方向:麻醉与镇痛。 E-mail: yh13285553263@163.com
  • 基金资助:
    国家自然科学基金(82271254)

Research progress of ketamine psychomimetic symptoms and reward mechanism

YANG Hang1, LU Fangzhou2, YANG Chun1, ZHU Wei1   

  1. 1The First Clinical College of Medicine, Nanjing Medical University, Nanjing 211166, Jiangsu, China; 2Department of Anesthesia and Perioperative Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu, China
  • Received:2022-09-01 Revised:2022-12-21 Online:2022-12-26 Published:2023-01-13

摘要: 氯胺酮是一种非选择性N-甲基-D-天冬氨酸(N-methyl-D-aspartic acid, NMDA)受体拮抗剂,近年来氯胺酮在神经精神疾病的治疗和研究中的地位举足轻重。氯胺酮拟精神作用和奖励通路的神经机制目前仍待完善,可能与大脑内多种神经元及通路密切相关,本文将对目前国内外相关研究进行综述并尝试整合已知的神经机制以及提出合理的假设。

关键词: 氯胺酮, 拟精神症状, 奖励, 神经机制, 药物依赖

Abstract: Ketamine is a non-selective N-methyl-D-aspartic acid (NMDA) receptor antagonist. Ketamine plays a significant role in the treatment and research of neuropsychiatric diseases in recent years. The neural mechanism of ketamine psychogenic effects and reward pathway remains to be perfected, which may be closely related to a variety of neurons and pathways in the brain. This paper intends to review the relevant studies at home and abroad, and try to integrate the known neural mechanisms and put forward reasonable hypotheses.

Key words: ketamine, psychomimetic symptoms, reward, neural mechanism, drug dependence

中图分类号: